The IPO Buzz: Bladder Cancer Biotech CG Oncology Increases IPO By 44 Percent
Someone involved in this deal must like the number 17: Bladder cancer biotech CG Oncology (CGON Proposed) upsized its IPO to 17 million shares – up from 11.8 million shares originally – and kept the price range at $16.00 to $18.00. If the upsized IPO is priced at the $17.00 mid-point, CG Oncology will raise $289.0 million – […]
January 23, 2024 Read More